1. Home
  2. Companies
  3. RNV
  4. Material Events

Renerve (ASX:RNV) — Material Events

ASX:RNV · 23 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 20 articles Notable 3 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
20
ReNerve Accelerates US Market Penetration with 80% Sales Surge and New ApprovalsMedium
ReNerve posts 80% sales growth, secures US hospital approvals, advances nerve repair products
30 Jan 2026 ·Quarterly Activities Report ·85
ReNerve Posts Record $211k Sales as Asia-Pacific Expansion AcceleratesMedium
ReNerve reports record sales, Asia-Pacific expansion, and $5M funding facility
29 July 2026 ·Quarterly Activities Report ·85
ReNerve Accelerates Global Nerve Repair Push with 80% Revenue Surge and FDA ProgressMedium
ReNerve reports strong revenue growth and advances nerve repair product pipeline with global expansion
19 Aug 2026 ·Company Presentation ·85
ReNerve Expands Into Indonesia With NervAlign Nerve Cuff ApprovalMedium
ReNerve gains marketing approval for NervAlign® Nerve Cuff in Indonesia, expanding Asia-Pacific footprint
6 July 2026 ·Regulatory Approval Announcement ·85
ReNerve Secures Indian Approval for NervAlign Nerve Cuff, Unlocking $700 Million MarketMedium
ReNerve Secures Indian Marketing Approval for NervAlign® Nerve Cuff
10 Aug 2026 ·Regulatory Approval Announcement ·85
ReNerve Expands Trial After Nerve Cuff Cuts Post-Surgery Pain DramaticallyMedium
ReNerve expands clinical trial for NervAlign® Nerve Cuff after positive interim results
5 Nov 2025 ·Clinical Trial Expansion Announcement ·85
ReNerve’s NervAlign® Nerve Cuff Wins US Military and Veterans ApprovalMedium
ReNerve’s NervAlign® Nerve Cuff Approved for US Military and Veterans Healthcare Systems with Initial Orders
13 Nov 2025 ·ASX Announcement ·85
ReNerve Posts 79% Sales Rise and Advances Nerve Guide Matrix Toward FDA SubmissionMedium
ReNerve reports 79% sales growth, regulatory approvals in Asia, and advances nerve repair product development
30 Apr 2026 ·Quarterly Activities Report ·85
ReNerve turns Asia-Pacific approvals into first Hong Kong and Malaysia surgeriesMedium
ReNerve begins commercial NervAlign sales in Hong Kong and Malaysia as FY26 revenue rises 88%
21 Sept 2026 ·Commercial and operational update ·82
ReNerve Expands Hong Kong Approval, Validates NervAlign® Nerve Cuff’s Clinical ImpactMedium
ReNerve secures expanded Hong Kong approval for NervAlign® Nerve Cuff, validating clinical benefits
12 Jan 2026 ·Regulatory Approval Announcement ·80
ReNerve Advances Nerve Guide Matrix to Critical Stage Ahead of FDA SubmissionMedium
ReNerve's NervAlign Nerve Guide Matrix Advances to Stage 3 Commercial Development Ahead of FDA Submission
15 Apr 2026 ·Product Development Update ·80
ReNerve Expands Asia-Pacific Reach with Philippines Marketing ApprovalMedium
ReNerve gains marketing approval for NervAlign® Nerve Cuff in the Philippines, expanding Asia-Pacific footprint
6 Aug 2026 ·Marketing Approval Announcement ·80
ReNerve Secures Exclusive Distribution Deal to Unlock 88 Million-Strong Greater Bay Area MarketMedium
ReNerve inks exclusive 3-year distribution deal with STC for Greater Bay Area market
1 June 2026 ·Distribution Agreement ·80
ReNerve Secures $3.2M to Boost US Sales and Launch New Nerve Repair ProductsMedium
ReNerve raises $3.2M to accelerate US sales and new product launches
20 Nov 2025 ·Capital Raising ·80
ReNerve Expands Asia-Pacific Reach with Malaysian Approval for NervAlign®Medium
ReNerve secures Malaysian approval for NervAlign® Nerve Cuff, advancing Asia-Pacific expansion
15 Jan 2026 ·ASX Announcement ·80
ReNerve Accelerates Global Nerve Repair Growth with 53% Revenue SurgeMedium
ReNerve reports 53% revenue growth, expands US distribution, advances clinical studies and global market approvals
27 Nov 2025 ·Corporate Presentation ·80
ReNerve reports 88% revenue growth as nerve repair pipeline moves toward commercialisationMedium
ReNerve reports 88% annual revenue growth and advances nerve repair pipeline
5 Oct 2026 ·Company Presentation ·78
ReNerve gains FDA clarity for NervAlign nerve guide submissionMedium
ReNerve receives positive FDA feedback for NervAlign Nerve Guide Matrix pathway
14 Oct 2026 ·Regulatory Update ·78
ReNerve Secures A$5 Million Convertible Note Facility to Fuel US Expansion and Product GrowthMedium
ReNerve secures up to A$5 million convertible note facility to fund growth and commercialisation
9 July 2026 ·Capital Raising ·75
ReNerve Accelerates Growth with 38% Sales Boost and New EmpliQ LaunchMedium
ReNerve reports 38% sales growth, launches EmpliQ products, advances nerve conduit development
23 Oct 2025 ·Quarterly Activities Report ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.